The seed round was led by Maurice Ferre and Arjun Desai to accelerate growth across the UK, Europe and the US.
"TympaHealth can deliver ear and hearing health services safely into the community and away from the hospital, expanding critical access for patients. It is doing so effectively in the UK and it is great to see an NHS innovation taking the next step of their journey."
The extension financing was led by Parkwalk to support clinical trials for the company's knee repair technology.
"This $12.5m Series A financing round from a range of high-quality medtech investors reflects the strong progress we are making with our award-winning FibroFix product platform. FibroFix is unique in emulating the functional properties of cartilage while also facilitating rapid tissue regeneration in patients suffering the debilitating effects of serious knee cartilage injuries. With our approach, there is significant bone sparing and strong tissue integration of the implant, which will result in much faster patient recovery from surgery."
Playfair Capital led the seed investment in Qureight, with backing from Meltwind, Ascension, and Cambridge Angels, to accelerate drug development partnerships.
"our next targets are pulmonary hypertension and adverse drug effects in complex lung cancer patients. This funding will allow us to use our platform to work with our biopharma partners to accelerate drug development in these areas."